Safety check of BCMA CAR T-cells made from your own immune cells
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign the consent form
- You can follow all trial visits and procedures (including the treatment timeline)
- Your illness is either relapsed/refractory multiple myeloma or relapsed/refractory diffuse large B-cell lymphoma, and you have measurable disease by specific lab/scan rules
- You have good overall strength, rated as ECOG 0–2 (a measure of how active you are)
- Your blood counts and organ tests (liver, kidneys, heart) are strong enough for treatment
- You do not have major pregnancy risk: if you can become pregnant or can father a child, you must use highly effective birth control as instructed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
This early-phase (Phase 1) trial tests a lab-made immune-cell treatment that targets two markers, BCMA and CD19, in people whose cancer has not responded to standard options. It’s meant to see if the treatment is safe and how well it can work in these cancers.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.